Apnimed, a late-stage drug developer focused on sleep apnea, leapt 38% on Friday after raising $192 million in an upsized US initial public offering. https://t.co/p0bC16q7bn ...

It's a huge day for healthcare numbers from earnings to trial data. So, we're seeing Novo in the red today after the drug maker set a heart drug failed to reduce major cardiovascular events compared to placebo in a late stage trial. The drug lowered markers of inflammation, but it did not translate to a lower risk of cardiovascular death, heart attack, or stroke.So, count analysts are calling this trial failure a major missed opportunity for Novo. You know, analysts have said that this drug represents a way ...

AbbVie reported second quarter profit and sales that topped Wall Street’s expectations, driven by strong demand across its immunology and neuroscience franchises and further signs of a recovery in Botox https://t.co/J0vcH1S0Vj ...

Novo Nordisk Wipes Out $30 Billion In Market Value After Failed Heart Drug Trialhttps://t.co/TrsLwvwLMk https://t.co/1imUbKaQOT ...

I want to start with a story. A 16-year-old kid from Long Island walks onto the stage of America's Got Talent. He's nervous.You can see it. He opens his mouth and within seconds the entire audience is on their feet. The judge has turned and one of them hit the golden buzzer.What the audience did didn't know and what was this moment extraordinary is that 2 years earlier this kid couldn't see the stage he was standing on. Christian Guardino was born with a single error, not a trauma, not an accident, but one ...

A Novo Nordisk experimental drug failed to reduce the risk of heart attacks and strokes in a large study, a blow to the drugmaker’s growth prospects beyond obesity and diabetes https://t.co/MFrUJa4F3r ...

Millions of people are now taking GLP-1 medications such as Zepbound, Wegovy and Ozempic. So taking a trip requires extra planning and preparation.Here are expert-backed tips to ensure a good trip: https://t.co/X2V9o92kXIPhoto: Indranil Mukherjee/AFP via Getty Images https://t.co/EPdEjp4vkm ...

India’s second-largest money manager is bullish on banks, oil refiners, power utilities and drugmakers, betting they are best placed to benefit from demand tailwinds despite a volatile global backdrop https://t.co/nHhVys7E55 ...